Session » RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1707

A Bioengineered Probiotic for the Oral Delivery of an Immunomodulator in Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1683

Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients

8:30AM-10:30AM: Abstract Number: 1703

AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1681

ATI-450, an Investigational MK2 Inhibitor, Is Well Tolerated and Demonstrated Clinical Activity in Patients with Mod/severe RA: A 12-week Phase 2a, Randomized, Investigator/patient-blind Study Investigating the Safety, Tolerability, PK and PD of ATI-450 + MTX vs PBO + MTX in MTX IR Patients

8:30AM-10:30AM: Abstract Number: 1710

Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial

8:30AM-10:30AM: Abstract Number: 1697

Clinical Outcomes up to Week 48 of Filgotinib Treatment in an Ongoing Long-term Extension Trial of RA Patients with Inadequate Response to MTX Initially Treated with Filgotinib or Adalimumab During the Phase 3 Parent Trial

8:30AM-10:30AM: Abstract Number: 1696

Clinical Outcomes up to Week 48 of Ongoing Filgotinib RA Long-term Extension Trial of Biologic DMARD Inadequate Responders Initially on Filgotinib or Placebo in a Phase 3 Trial

8:30AM-10:30AM: Abstract Number: 1679

Effectiveness and Safety of Tocilizumab SC Every 10 Days in Patients with Rheumatoid Arthritis Who Previously Used Tocilizumab EV During the COVID 19 Pandemic at the Hospital Docente Padre Billini, Dominican Republic

8:30AM-10:30AM: Abstract Number: 1674

Effectiveness and Safety of Tofacitinib in Canadian Patients with RA: Primary Results from a Multicenter, Observational Study

8:30AM-10:30AM: Abstract Number: 1677

Effects of Biological-DMARDs on the Serum Low-density Lipoprotein (LDL) / High-density Lipoprotein (HDL) – Cholesterol Ratio in Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1702

Efficacy and Safety of Baricitinib in B/tsDMARDs Naive and B/tsDMARDs-IR Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1685

Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – Placebo and Active Controlled Study

8:30AM-10:30AM: Abstract Number: 1686

Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy

8:30AM-10:30AM: Abstract Number: 1695

Erythrocyte Methotrexate Polyglutamates Are Substantially Higher After Subcutaneous Methotrexate Treatment in Rheumatoid Arthritis Patients in the First Months of Treatment

8:30AM-10:30AM: Abstract Number: 1701

Evaluation of Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis Patients, Treated with Biological Agents: 6-month Follow-up

8:30AM-10:30AM: Abstract Number: 1678

Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial

8:30AM-10:30AM: Abstract Number: 1680

Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials

8:30AM-10:30AM: Abstract Number: 1682

Impact of Type, Dose and Duration of Oral Polyunsaturated Fatty Acid Supplementation on Disease Activity in Inflammatory Rheumatic Diseases: A Systematic Literature Review and Meta-analysis

8:30AM-10:30AM: Abstract Number: 1684

Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

8:30AM-10:30AM: Abstract Number: 1687

Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial

8:30AM-10:30AM: Abstract Number: 1698

Integrated Safety Analysis Update for Filgotinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Receiving Treatment over a Median of 2.2 Years

8:30AM-10:30AM: Abstract Number: 1692

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: 3-year Results from the SELECT-EARLY Study

8:30AM-10:30AM: Abstract Number: 1709

Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial

8:30AM-10:30AM: Abstract Number: 1691

Long-Term Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis

8:30AM-10:30AM: Abstract Number: 1693

Lower Adverse Event and Infection Rates During Tocilizumab Therapy Without Concomitant GC: An Analysis of the ICHIBAN Study

8:30AM-10:30AM: Abstract Number: 1700

Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib

8:30AM-10:30AM: Abstract Number: 1675

Risk of Malignancy in Patients Treated with Tofacitinib: Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study

8:30AM-10:30AM: Abstract Number: 1690

Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies

8:30AM-10:30AM: Abstract Number: 1676

Safety of Baricitinib in Japanese Patients with Rheumatoid Arthritis (RA): The 2020 Interim Report from All-case Post Marketing Surveillance in Clinical Practice

8:30AM-10:30AM: Abstract Number: 1688

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 9.3 Years: An Updated Integrated Safety Analysis

8:30AM-10:30AM: Abstract Number: 1689

Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody

8:30AM-10:30AM: Abstract Number: 1694

Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs

8:30AM-10:30AM: Abstract Number: 1699

The “ITIS” Diet Improves Fatigue in Patients with Rheumatoid Arthritis and Is Associated with Changes in Metabolome and Fecal Microbiome

8:30AM-10:30AM: Abstract Number: 1708

The Efficacy and Safety of Piclidenoson vs Methotrexate in Early Rheumatoid Arthritis: Phase 3 Randomized, Double-blind, Placebo-controlled Study

8:30AM-10:30AM: Abstract Number: 1705

The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users

8:30AM-10:30AM: Abstract Number: 1704

Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months?

8:30AM-10:30AM: Abstract Number: 1706

Twenty-four-week Follow-up of a Randomized Controlled First-in-Human Trial of the Safety and Efficacy of Neurostimulation with a Miniaturized Vagus Nerve Stimulation Device in Patients with Multidrug-Refractory Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].